Vanja Kunkin

Dr. Vanja Kunkin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VZVesna Zeljković
Vesna Zeljković
MBMirjana A. Bogavac
Mirjana A. Bogavac
MDMilan Dekic
Milan Dekic
SMSlaviša Minić
Slaviša Minić
EMElvis Mahmutovic
Elvis Mahmutovic
Maja KaramanMaja Karaman
Maja Karaman
Background:Cancer remains a major global health challenge, with treatment efficacy li-mited by drug resistance and adverse effects. Drug repurposing offers opportunities for novel anticancer strategies. This study evaluated the cytotoxic, antiproliferative, and pro-apoptotic effects of metformin and caffeine, alone and in combination, in human cancer cell lines, and their potentialinteraction mechanisms. Methods:Human cervical carcinoma (HeLa), lung adenocarcinoma (A549), and colorectal carcinoma (HT29) cell lines were treated with metformin (0.05–50 mM) and caffeine (0.5–5 mM), alone or combined, for 24 and 48 h. Cell viability and proliferation were assessed using Trypan Blue and sulforhodamine B (SRB) assays. Apoptosis was analyzed by Annexin V/propidium iodide flow cytometry, and p53 expression in HeLa cells was determined by ELISA. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test. Results:Metformin induced dose- and time-dependent cytotoxicity in all tested cell lines, with the lowest IC₅₀ values observed in HeLa and A549 cells after 48 h (2.28 and 3.30 mM, respectively; p < 0.05). Caffeine showed moderate antiproliferative activity, with the strongest effects at 2.03 mM in HeLa and 2.01 mM in HT29 cells (p < 0.05). The combined treatment produced effects that varied depending on both the cell line and exposure time. At earlier time points, transient synergistic effects were observed in certain cell lines, particularly HeLa; however, these effects were not sustained over time. With prolonged exposure, the interaction shifted toward predominantly antagonistic effects, indicating a reduced overall efficacy of the combination compared to expected additive outcomes.Increased apoptosis and elevated p53 expression further support the activation of tumor-suppressive pathways. Conclusions:Metformin exhibits significant anticancer activity in vitro, supporting met-formin repurposing in oncology. However,the addition of caffeine does not uniformly enhance its efficacy and appears to exert context-dependent effects.Further in vivo studies are required to confirm its clinical relevance. Keywords:AMPK;Antitumor activity; Apoptosis; Caffeine; Cancer cell lines;Chou–Talalay method; Drug repurposing;Docking;Metfomin;Molecular docking; p53;

29 May 2026 in Molecules
Verified
Journal Article
Open access
PDF file
VZVesna Zeljković
Vesna Zeljković
MBMirjana A. Bogavac
Mirjana A. Bogavac
MDMilan Dekic
Milan Dekic
SMSlaviša Minić
Slaviša Minić
EMElvis Mahmutovic
Elvis Mahmutovic
Maja KaramanMaja Karaman
Maja Karaman
Background: Cancer remains a major global health challenge, with treatment efficacy often limited by drug resistance and adverse effects. Drug repurposing offers promising opportunities for developing novel anticancer strategies. This study evaluated the cytotoxic, antiproliferative, and pro-apoptotic effects of metformin and caffeine, administered individually and in combination, in human cancer cell lines, as well as their potential interaction mechanisms. Methods: Human cervical carcinoma (HeLa), lung adenocarcinoma (A549), and colorectal carcinoma (HT29) cell lines were treated with metformin (0.05–50 mM) and caffeine (0.5–5 mM), either alone or in combination, for 24 and 48 h. Cell viability and proliferation were assessed using Trypan Blue and sulforhodamine B (SRB) assays. Apoptosis was analyzed by Annexin V/propidium iodide flow cytometry, and p53 expression in HeLa cells was determined by ELISA. Statistical analysis was performed using a one-way ANOVA followed by Tukey’s post hoc test. Results: Metformin induced dose- and time-dependent cytotoxicity in all tested cell lines, with the lowest IC50 values observed in HeLa and A549 cells after 48 h (2.28 and 3.30 mM, respectively; p < 0.05). Caffeine showed moderate antiproliferative activity, with the strongest effects observed at 2.03 mM in HeLa cells and 2.01 mM in HT29 cells (p < 0.05). The combined treatment produced effects that varied depending on both the cell line and exposure time. At earlier time points, transient synergistic effects were observed in certain cell lines, particularly HeLa cells; however, these effects were not sustained over time. With prolonged exposure, the interaction shifted predominantly toward antagonistic effects, indicating the reduced overall efficacy of the combination compared with the expected additive outcomes. Increased apoptosis and elevated p53 expression further supported the activation of tumor-suppressive pathways. Conclusions: Metformin exhibited significant anticancer activity in vitro, supporting its potential repurposing in oncology. However, the addition of caffeine did not uniformly enhance its efficacy and appeared to exert context-dependent effects. Further in vivo studies are required to confirm the clinical relevance of these findings.

7 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
VZVesna Zeljković
Vesna Zeljković
SMSlaviša Minić
Slaviša Minić
MMMarko Mladenović
Marko Mladenović
Dejan MilenkovićDejan Milenković
Dejan Milenković
Zoran S. MarkovićZoran S. Marković
Zoran S. Marković
Maja KaramanMaja Karaman
Maja Karaman
Background: Metabolic reprogramming enables cancer cells to adapt to energetic stress and sustain proliferation. Simultaneous inhibition of glycolysis and mitochondrial respiration has emerged as a promising strategy to overcome metabolic plasticity. This study evaluated the antiproliferative effects of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) alone and in combination with metformin in human cancer cell lines. Methods: Human cervical carcinoma (HeLa), lung adenocarcinoma (A549), colorectal adenocarcinoma (HT-29), and normal lung fibroblasts (MRC-5) were treated with 2-DG or metformin individually, or with metformin in the presence of a fixed concentration of 2-DG (1 mM). Cell viability was assessed using the sulforhodamine B assay after 24 and 48 h. IC50 values were calculated by nonlinear regression, Dose Reduction Index (DRI) analysis evaluated sensitization to metformin, and molecular docking was performed to investigate interactions with selected metabolic targets. Results: Both 2-DG and metformin inhibited cell proliferation in a concentration- and time-dependent manner. HeLa cells were the most sensitive to glycolytic inhibition, while A549 and HT-29 cells showed moderate susceptibility. Co-treatment with 2-DG significantly enhanced metformin activity, reducing its IC50 in HeLa cells from 6.04 to 2.00 mM after 24 h and from 2.28 to 1.56 mM after 48 h. DRI analysis demonstrated increased sensitivity to metformin in all cancer cell lines, particularly HT-29 and A549, whereas normal MRC-5 fibroblasts remained comparatively less affected. Molecular docking revealed favorable binding of both 2-DG and metformin to proteins involved in cellular energy metabolism. Conclusions: Combined inhibition of glycolysis and mitochondrial respiration potentiates the antiproliferative effects of metformin, increases metabolic vulnerability in cancer cells, and is supported by molecular docking evidence of interactions with metabolic targets, while showing limited toxicity toward normal fibroblasts. These findings support dual metabolic targeting as a promising therapeutic strategy and warrant further mechanistic and in vivo studies.

1 January 2022 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
VKVanja Kunkin
Vanja Kunkin
AOAleksandar Ognjenovic
Aleksandar Ognjenovic
Introduction. Solitary cecal ulcer is a benign and extremely rare disease, as less than 300 cases have been reported so far. The etiology is unknown, and it can be diagnosed by pathohistological examination. Often presented as an acute abdomen and rectal bleeding, it can mock various important and urgent conditions. Treatment protocol is not defined. Extensive and radical surgeries are often performed due to this benign disease mimic. Our aim was to indicate this disease, present the treatment of this rare condition, and to facilitate the treatment plan for this disease. Case outline. Female, aged 67, was admitted to the Emergency Department with a clinical manifestation of acute appendicitis. Emergency surgery was indicated after following diagnostic tests. The intraoperative finding revealed an ulcer on the cecum, which was sutured. The patient fully recovered, and subsequent colonoscopy and pathohistological findings indicated a solitary ulcer. Conclusion. It is possible to treat this condition by retaining the organ and avoiding major surgery. Therefore, it is our opinion that it might provide significant assistance to clinicians in a similar situation. Hence, it is undoubtedly an interesting case for archiving, especially since such a case has not been recorded in our country yet.

27 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VZVesna Zeljković
Vesna Zeljković
MBMirjana A. Bogavac
Mirjana A. Bogavac
MDMilan Dekić
Milan Dekić
SMSlaviša Minić
Slaviša Minić
EMElvis Mahmutović
Elvis Mahmutović
Maja KaramanMaja Karaman
Maja Karaman
Background: Cancer remains a major global health challenge, with treatment efficacy limited by drug resistance and adverse effects. Drug repurposing offers opportunities for novel anticancer strategies. This study evaluated the cytotoxic, antiproliferative, and pro-apoptotic effects of metformin and caffeine, alone and in combination, in human cancer cell lines, and their potentialinteraction mechanisms. Methods: Human cervical carcinoma (HeLa), lung adenocarcinoma (A549), and colorectal carcinoma (HT29) cell lines were treated with metformin (0.05–50 mM) and caffeine (0.5–5 mM), alone or combined, for 24 and 48 h. Cell viability and proliferation were assessed using Trypan Blue and sulforhodamine B (SRB) assays. Apoptosis was analyzed by Annexin V/propidium iodide flow cytometry, and p53 expression in HeLa cells was determined by ELISA. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test. Results: Metformin induced dose- and time-dependent cytotoxicity in all cell lines, with the lowest IC₅₀ values in HeLa and A549 cells after 48 h (2.28 and 3.30 mM; p < 0.05). Caffeine showed moderate antiproliferative activity, with strongest effects at 2.03 mM in HeLa and 2.01 mM in HT29 cells (p < 0.05). Combined treatment demonstrated variable effects depending on the cell line and treatment duration, with limited synergistic interaction observed only under specific conditions, while predominantly antagonistic effects were detected overall. Increased apoptosis and elevated p53 expression suggest activation of tumor-suppressive pathways. Conclusions: Metformin exhibits significant anticancer activity in vitro, supporting metformin repurposing in oncology. However,the addition of caffeine does not uniformly enhance its efficacy and appears to exert context-dependent effects.Further in vivo studies are required to confirm its clinical relevance.

1 January 2025 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
VKVanja Kunkin
Vanja Kunkin
VZVesna Zeljković
Vesna Zeljković
Introduction/Objective. The objective of the study was to determine whether the local application of tranexamic acid (TXA) by pouring over the surgical wound reduces the incidence of postoperative hematoma and the occurrence of postoperative bleeding in the wound following inguinal hernia repair using the Lichtenstein technique. Methods. We conducted a prospective, randomized, double-blind clinical study in the period from June 2024 to February 2025. One hundred and twenty patients were divided into two groups, one group of patients who received TXA during surgery, and the other group where a placebo was administered. Subsequently, the groups were compared and analyzed by sex and age structure, the frequency of postoperative hematoma, and the pre- and postoperative levels of erythrocytes, hemoglobin, and platelets were recorded. Results. The results indicate that in the group where TXA was administered, postoperative hematoma occurred statistically significantly less often than in the group with a placebo (p < 0.05). The frequency of postoperative hematoma in the group of patients who were treated with TXA was 3.8%, while the frequency in the group of patients who were treated with a placebo was 13%. There was a statistically significant difference in the levels of platelets before and after surgery in the compared groups. Conclusion. We found that the topical application of TXA reduces the occurrence of postoperative hematoma, and thus the occurrence of postoperative bleeding, as well as reduces the postoperative drop in platelets.